Clinical safety and effects of tigecycline combinations on treatment patients with carbapenem-resistant Acinetobacter baumannii pulmonary infection
OBJECTIVE To observe the clinical effects of tigecycline combined with cefoperazone-sulbactam(CS)and carbapenems(meropenem,imipenem cilastatin sodium and biapenem)on treatment of the patients with car-bapenem-resistant Acinetobacter baumannii(CRAB)pulmonary infection and analyze the safety.METHODS The patients with CRAB pulmonary infection who were given tigecycline combined with CS(the T+CS group,43 ca-ses)and tigecycline combined with carbapenems(the T+C group,47 cases)were recruited as the research sub-jects.The clinical data and clinical outcomes were observed and compared between the two groups of patients.The difference in survival curve between the two groups was assessed by Kaplan-Meier method.RESULTS The baseline clinical data of the two groups were similar.There were no significant differences in age,gender,under-lying disease,status of complication with infection and laboratory test indexes between the two groups.The num-ber of the patients who received enteral nutrition therapy and had septic shock was larger in the T+C group than in the T+CS group(P＜0.05).The 30-day mortality rate and the failed rate of eradication of microorganisms of the T+C group were higher than those of the T+CS group(P＜0.05).The result of Log-Rank test indicated that there was significant difference in the survival curve between the two groups of patients(P＜0.05).CONCLUSION Tigecycline combined with cefoperazone-sulbactam is more valuable than the combination with carbapenems for treatment of the patients with CRAB pulmonary infection.
NETL
NSTL
万方数据
维普
